American Journal of Kidney Diseases
Volume 53, Issue 6 , Pages 1068-1081 , June 2009

The Importance of Residual Kidney Function for Patients on Dialysis: A Critical Review

  • Jeffrey Perl, MD
    • ,
  • Joanne M. Bargman, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Joanne M. Bargman, MD, 8NU-840, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4

Received 27 November 2008 ,Accepted 6 February 2009.

References 

  1. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA Study. J Am Soc Nephrol. 2001;12:2158–2162
  2. Maiorca R, Brunori G, Zubani R, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients (A longitudinal study). Nephrol Dial Transplant. 1995;10:2295–2305
  3. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13:1307–1320
  4. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang SM, Zhu X, Lazarus JM. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis. 1999;33:523–534
  5. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;38:85–90
  6. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004;15:1061–1070
  7. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis. 2003;41:1293–1302
  8. Rocco M, Soucie JM, Pastan S, McClellan WM. Peritoneal dialysis adequacy and risk of death. Kidney Int. 2000;58:446–457
  9. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(suppl 1):S144–S150
  10. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol. 1996;7:198–207
  11. Hsu CY, Chertow GM, Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int. 2002;61:1567–1576
  12. Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant. 2007;22:1633–1638
  13. Delaney MP, Stevens PE, Al Hasani M, Stowe HJ, Judge C, Lamb EJ. Relationship of serum cystatin C to peritoneal and renal clearance measures in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2008;51:278–284
  14. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000. Am J Kidney Dis. 2001;37(suppl):S7–S64
  15. Korevaar JC, Jansen MA, Dekker FW, et al. When to initiate dialysis: Effect of proposed US guidelines on survival. Lancet. 2001;358:1046–1050
  16. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol. 2002;13:2125–2132
  17. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  18. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000;11:556–564
  19. Johnson DW, Mudge DW, Sturtevant JM, et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int. 2003;23:276–283
  20. Davies SJ. Peritoneal dialysis in the patient with a failing renal allograft. Perit Dial Int. 2001;21(suppl 3):S280–S284
  21. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int. 2000;20:429–438
  22. Holley JL, Aslam N, Bernardini J, Fried L, Piraino B. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit Dial Int. 2001;21:302–305
  23. Liao CT, Shiao CC, Huang JW, et al. Predictors of faster decline of residual renal function in Taiwanese peritoneal dialysis patients. Perit Dial Int. 2008;28(suppl 3):S191–S195
  24. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant. 2001;16:2207–2213
  25. Shin SK, Noh H, Kang SW, et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999;19:138–142
  26. Go A, Chertow G, Fan D, McCulloch C, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  27. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–495
  28. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315
  29. Wang AY. Cardiovascular risk factors in peritoneal dialysis patients revisited. Perit Dial Int. 2007;27(suppl 2):S223–S227
  30. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003;64:2238–2243
  31. Pham NM, Recht NS, Hostetter TH, Meyer TW. Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol. 2008;3:85–90
  32. Maeda K, Shinzato T, Ota T, et al. Beta-2-microglobulin generation rate and clearance rate in maintenance hemodialysis patients. Nephron. 1990;56:118–125
  33. Amici G, Virga G, Da Rin G, et al. Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. Nephron. 1993;65:469–471
  34. Ates K, Nergizoglu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int. 2001;60:767–776
  35. Konings CJ, Kooman JP, Schonck M, et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: Evidence from a longitudinal study. Nephrol Dial Transplant. 2003;18:797–803
  36. Cheng LT, Chen W, Tang W, Wang T. Residual renal function and volume control in peritoneal dialysis patients. Nephron Clin Pract. 2006;104:c47–c54
  37. Tsuang DW, Skol AD, Faraone SV, et al. Examination of genetic linkage of chromosome 15 to schizophrenia in a large Veterans Affairs Cooperative Study sample. Am J Med Genet. 2001;105:662–668
  38. Wang AY, Wang M, Woo J, et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int. 2002;62:639–647
  39. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–192
  40. Wang AY, Wang M, Woo J, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:2186–2194
  41. Silberberg JS, Rahal DP, Patton DR, Sniderman AD. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol. 1989;64:222–224
  42. Yavuz A, Ersoy FF, Passadakis PS, et al. Phosphorus control in peritoneal dialysis patients. Kidney Int Suppl. 2008;108:S152–S158
  43. Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: What are the implications?. Am J Kidney Dis. 2004;43:712–720
  44. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
  45. Morduchowicz G, Winkler J, Zabludowski JR, Boner G. Effects of residual renal function in haemodialysis patients. Int Urol Nephrol. 1994;26:125–131
  46. Huang WH, Chen KH, Hsu CW, et al. Residual renal function—One of the factors associated with arterial stiffness in peritoneal dialysis patients (Insight from a retrospective study in 146 peritoneal dialysis patients). Blood Purif. 2008;26:133–137
  47. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int. 2006;69:1726–1732
  48. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002;13(suppl 1):S28–S36
  49. Wang AY, Lam CW, Wang M, et al. Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: A prospective cohort study. Am J Nephrol. 2008;28:647–653
  50. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005;16(suppl 1):S83–S88
  51. Wang AY, Woo J, Lam CW, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?. J Am Soc Nephrol. 2003;14:1871–1879
  52. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–1218
  53. Chung SH, Heimburger O, Stenvinkel P, Bergstrom J, Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant. 2001;16:2240–2245
  54. Chung SH, Heimburger O, Stenvinkel P, Qureshi AR, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant. 2003;18:590–597
  55. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol. 1993;150:2007–2017
  56. Witko-Sarsat V, Descamps-Latscha B. Advanced oxidation protein products: Novel uraemic toxins and pro-inflammatory mediators in chronic renal failure?. Nephrol Dial Transplant. 1997;12:1310–1312
  57. Suda T, Hiroshige K, Ohta T, et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant. 2000;15:396–401
  58. Wang AY, Sea MM, Ip R, et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 2001;12:2450–2457
  59. Wang AY, Sea MM, Ip R, et al. Independent effects of residual renal function and dialysis adequacy on dietary micronutrient intakes in patients receiving continuous ambulatory peritoneal dialysis. Am J Clin Nutr. 2002;76:569–576
  60. Szeto CC, Lai KN, Wong TY, et al. Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1999;34:1056–1064
  61. Wang AY, Sea MM, Ho ZS, Lui SF, Li PK, Woo J. Evaluation of handgrip strength as a nutritional marker and prognostic indicator in peritoneal dialysis patients. Am J Clin Nutr. 2005;81:79–86
  62. Wang AY, Sea MM, Tang N, et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:3134–3143
  63. Han SH, Lee SC, Ahn SV, et al. Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant. 2007;22:2653–2658
  64. Perez Fontan M, Rodriguez-Carmona A, Garcia-Naveiro R, Rosales M, Villaverde P, Valdes F. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int. 2005;25:274–284
  65. Liu YL, Huang CC, Kao MT. Residual renal function predicts outcome of fungal peritonitis in peritoneal dialysis patients. Perit Dial Int. 2006;26:407–409
  66. Rottembourg J, Issad B, Gallego JL, et al. Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc. 1983;19:397–403
  67. Lysaght MJ, Vonesh EF, Gotch F, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans. 1991;37:598–604
  68. Misra M, Vonesh E, Van Stone JC, Moore HL, Prowant B, Nolph KD. Effect of cause and time of dropout on the residual GFR: A comparative analysis of the decline of GFR on dialysis. Kidney Int. 2001;59:754–763
  69. Lang SM, Bergner A, Topfer M, Schiffl H. Preservation of residual renal function in dialysis patients: Effects of dialysis-technique-related factors. Perit Dial Int. 2001;21:52–57
  70. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: What do they tell us?. Kidney Int Suppl. 2006;103:S3–S11
  71. McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR. Relationship between dialysis modality and mortality. J Am Soc Nephrol. 2009;20:155–163
  72. Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med. 2005;143:174–183
  73. Hakim RM. Clinical implications of biocompatibility in blood purification membranes. Nephrol Dial Transplant. 2000;15(suppl 2):S16–S20
  74. Pertosa G, Grandaliano G, Gesualdo L, Schena FP. Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl. 2000;76:S104–S111
  75. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant. 2002;17:1814–1818
  76. McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis. 1997;29:576–583
  77. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis. 1997;30:366–373
  78. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int. 2002;61:256–265
  79. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol. 2000;11:116–125
  80. Hufnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant. 1999;14:1224–1228
  81. Hiroshige K, Yuu K, Soejima M, Takasugi M, Kuroiwa A. Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int. 1996;16:307–315
  82. de Fijter CW, ter Wee PM, Donker AJ. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant. 2000;15:1094–1096
  83. Bro S, Bjorner JB, Tofte-Jensen P, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int. 1999;19:526–533
  84. Rodriguez AM, Diaz NV, Cubillo LP, et al. Automated peritoneal dialysis: A Spanish multicentre study. Nephrol Dial Transplant. 1998;13:2335–2340
  85. Rabindranath KS, Adams J, Ali TZ, Daly C, Vale L, Macleod AM. Automated vs continuous ambulatory peritoneal dialysis: A systematic review of randomized controlled trials. Nephrol Dial Transplant. 2007;22:2991–2998
  86. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002;62:1046–1053
  87. Gunal AI, Duman S, Ozkahya M, et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis. 2001;37:588–593
  88. van Olden RW, Guchelaar HJ, Struijk DG, Krediet RT, Arisz L. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int. 2003;23:339–347
  89. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59:1128–1133
  90. Davies SJ, Garcia Lopez E, Woodrow G, et al. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant. 2008;23:2982–2988
  91. John B, Daley J, Davies SJ. Plasma volume is normal in PD patients despite a ratio of increased extracellular fluid to total body water. Perit Dial Int. 2008;28(suppl 4):S81A
  92. Breborowicz A, Pawlaczyk K, Polubinska A, et al. Effect of peritoneal dialysis on renal morphology and function. Nephrol Dial Transplant. 2006;21:3539–3544
  93. Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004;66:408–418
  94. Montenegro J, Saracho R, Gallardo I, Martinez I, Munoz R, Quintanilla N. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant. 2007;22:1703–1708
  95. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function. Kidney Int. 2008;73:200–206
  96. Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—A 1-year randomized control trial. Nephrol Dial Transplant. 2007;22:552–559
  97. Erixon M, Wieslander A, Linden T, et al. How to avoid glucose degradation products in peritoneal dialysis fluids. Perit Dial Int. 2006;26:490–497
  98. Ortiz A, Wieslander A, Linden T, et al. 3,4-DGE is important for side effects in peritoneal dialysis what about its role in diabetes. Curr Med Chem. 2006;13:2695–2702
  99. Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int. 2003;63:1556–1563
  100. Rodriguez-Carmona A, Perez Fontan M, Garcia Lopez E, Garcia Falcon T, Diaz Cambre H. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: A randomized crossover study. Perit Dial Int. 2007;27:260–266
  101. Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial. J Am Soc Nephrol. 2003;14:2338–2344
  102. Konings CJ, Kooman JP, Gladziwa U, van der Sande FM, Leunissen KM. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int. 2005;67:1190–1191
  103. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–364
  104. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy (The Collaborative Study Group). N Engl J Med. 1993;329:1456–1462
  105. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis. 2004;43:1056–1064
  106. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis (A randomized, controlled study). Ann Intern Med. 2003;139:105–112
  107. Fang W, Oreopoulos DG, Bargman JM. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant. 2008;23:3704–3710
  108. Spital A, Stems RH. Potassium homeostasis in dialysis patients. Semin Dial. 1988;1:14–20
  109. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis. 1999;34:14–20
  110. Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis. 2003;41:670–675
  111. Lui SL, Cheng SW, Ng F, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: Effect on residual renal function. Kidney Int. 2005;68:2375–2380
  112. Weisbord SD, Bernardini J, Mor MK, et al. The effect of coronary angiography on residual renal function in patients on peritoneal dialysis. Clin Cardiol. 2006;29:494–497
  113. Dittrich E, Puttinger H, Schillinger M, et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients—A prospective study. Nephrol Dial Transplant. 2006;21:1334–1339
  114. Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant. 2006;21:1040–1045
  115. Jassal SV, Lok CE, Walele A, Bargman JM. Continued transplant immunosuppression may prolong survival after return to peritoneal dialysis: Results of a decision analysis. Am J Kidney Dis. 2002;40:178–183
  116. Jindal KK, Hirsch DJ. Long-term peritoneal dialysis in the absence of residual renal function. Perit Dial Int. 1996;16:78–81

 Originally published online as doi:10.1053/j.ajkd.2009.02.012 on April 27, 2009.

PII: S0272-6386(09)00446-6

doi: 10.1053/j.ajkd.2009.02.012

American Journal of Kidney Diseases
Volume 53, Issue 6 , Pages 1068-1081 , June 2009

Article Tools

* Image Usage & Resolution